107 related articles for article (PubMed ID: 25647738)
21. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
23. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
24. Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549.
Tièche CC; Gao Y; Bührer ED; Hobi N; Berezowska SA; Wyler K; Froment L; Weis S; Peng RW; Bruggmann R; Schär P; Amrein MA; Hall SRR; Dorn P; Kocher G; Riether C; Ochsenbein A; Schmid RA; Marti TM
Neoplasia; 2019 Feb; 21(2):185-196. PubMed ID: 30591423
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-β1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line.
Xu Y; Lu S
Mol Med Rep; 2015 Jan; 11(1):417-21. PubMed ID: 25323156
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
27. Degradation of Mcl-1 through GSK-3β Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells.
Kang XH; Zhang JH; Zhang QQ; Cui YH; Wang Y; Kou WZ; Miao ZH; Lu P; Wang LF; Xu ZY; Cao F
Cell Physiol Biochem; 2017; 41(5):2067-2076. PubMed ID: 28419994
[TBL] [Abstract][Full Text] [Related]
28. Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture.
Kim SH; Choe C; Shin YS; Jeon MJ; Choi SJ; Lee J; Bae GY; Cha HJ; Kim J
Anticancer Res; 2013 May; 33(5):2001-9. PubMed ID: 23645749
[TBL] [Abstract][Full Text] [Related]
29. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
30. KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells.
Kang MJ; Yun HH; Lee JH
Biochem Biophys Res Commun; 2017 Oct; 492(3):304-309. PubMed ID: 28859986
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer.
Shen W; Pang H; Liu J; Zhou J; Zhang F; Liu L; Ma N; Zhang N; Zhang H; Liu L
Oncol Res; 2014; 22(1):47-55. PubMed ID: 25700358
[TBL] [Abstract][Full Text] [Related]
32. Leptin promotes metastasis by inducing an epithelial-mesenchymal transition in A549 lung cancer cells.
Feng H; Liu Q; Zhang N; Zheng L; Sang M; Feng J; Zhang J; Wu X; Shan B
Oncol Res; 2013; 21(3):165-71. PubMed ID: 24512731
[TBL] [Abstract][Full Text] [Related]
33. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
Ju L; Zhou C
Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972
[TBL] [Abstract][Full Text] [Related]
34. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
[TBL] [Abstract][Full Text] [Related]
35. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer.
Nakano T; Go T; Nakashima N; Liu D; Yokomise H
Anticancer Res; 2020 Feb; 40(2):1007-1014. PubMed ID: 32014946
[TBL] [Abstract][Full Text] [Related]
37. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions.
Lee JG; Shin JH; Shim HS; Lee CY; Kim DJ; Kim YS; Chung KY
Respir Res; 2015 Nov; 16():138. PubMed ID: 26553068
[TBL] [Abstract][Full Text] [Related]
38. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
Chanvorachote P; Pongrakhananon V; Wannachaiyasit S; Luanpitpong S; Rojanasakul Y; Nimmannit U
Cancer Invest; 2009 Jul; 27(6):624-35. PubMed ID: 19283527
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
40. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
